Evidence map›Paper›PMID 40330788›Full record

ArticleCurrent medical mycology2024

Evaluation of the efficacy of novel topical antifungal agents against dermatophytes in North India: A prospective study.

Tanya Sachan, Prashant Gupta, Swastika Suvirya, Parul Verma, Raj Kumar Kalyan, Gopa Banerjee

Abstract read
In one paragraph

Article in Current medical mycology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tanya SachanDepartment of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Prashant GuptaDepartment of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Swastika SuviryaDepartment of Dermatology, Venerology, and Leprosy, King George's Medical University, Lucknow, Uttar Pradesh, India.
Parul VermaDepartment of Dermatology, Venerology, and Leprosy, King George's Medical University, Lucknow, Uttar Pradesh, India.
Raj Kumar KalyanDepartment of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Gopa BanerjeeDepartment of Microbiology, King George's Medical University, Lucknow, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: Dermatophytosis, a fungal infection targeting keratinized tissue, is caused by dermatophytes, commonly affecting skin, hair, and nails. Prevalent in tropical regions, such as India, its treatment typically utilizes systemic and topical antifungal medications. Despite ample research on oral antifungals, data on the susceptibility of topical treatments, especially in India, where they are prevalent, remains scarce. This study aimed to investigate the antifungal susceptibility of efinaconazole, tavaborole, luliconazole, and sertaconazole against dermatophytes isolated from cases of dermatophytosis. Materials and Methods: Samples of all the clinically diagnosed cases of dermatophytosis were subjected to microscopy and culture. All 204 dermatophytes, namely Results: The minimum inhibitory concentration values for efinaconazole, tavaborole, sertaconazole, and luliconazole were within the ranges of 0.008-0.5, 1-2, 0.128-2, and 0.004-0.008 µg/ml, respectively across all dermatophytes. Epidemiological cutoff values (ECVs) were 0.004 µg/ml for luliconazole and 2 µg/ml for tavaborole for all dermatophytes. Sertaconazole ECVs were 2 µg/ml for Conclusion: The results from the present study on the

Indexed as

AntifungalsAntifungal SusceptibilityDermatophytesECVTopical

Identifiers

PMID40330788
PMCPMC12050482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.